Sign Out
Thyrotrophic adenoma
Adult: In patients where surgery and/or radiotherapy were unable to lower the thyroid-stimulating hormone level: Initially, 30 mg once every 14 days, increased to 30 mg once every 10 days according to patient’s response.
Intramuscular
Acromegaly, Carcinoid syndrome
Adult: In patients with acromegaly where surgery and/or radiotherapy were unable to normalise the GH and/or IGF-1 levels: Initially, 30 mg once every 14 days, increased to 30 mg once every 7-10 days according to patient’s response.
Subcutaneous
Acromegaly
Adult: In patients with inadequate response to surgery and/or radiotherapy: Initially, 90 mg via deep SC injection once every 4 weeks (28 days) for 3 months. Dosage is individualised according to patient’s response, GH and/or IGF-1 (refer to country- or product-specific detailed product guideline). Dosing recommendations may vary among countries or individual products, refer to country- or product-specific detailed product guideline).
Subcutaneous
Gastroenteropancreatic neuroendocrine tumours
Adult: In patients with unresectable, well- or moderately differentiated, locally advanced or metastatic cases: 120 mg via deep SC injection once every 4 weeks (28 days) continued until disease progression or unmanageable toxicity.
Subcutaneous
Carcinoid syndrome
Adult: 60-120 mg via deep SC injection once every 4 weeks (28 days). Dose is adjusted according to patient’s response. May not give additional dose if the patient is already receiving treatment for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
